Article
HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair.
Carcinogenesis - 21 Nov 2025
Liu Weiqi, Liu Yulian, Xie Yun, Huang Hui, Wan Mengzhi, Zhou Ling, Xu Fei, Zhong Min
Abstract excerpt
Nonsmall cell lung cancer (NSCLC) harboring EGFR mutations, including the resistant T790M variant, continues to require improved therapeutic strategies despite the development of EGFR tyrosine kinase inhibitors (TKIs). This study evaluates the radiosensitizing potential of HS-10296 (almonertinib), a third-generation EGFR-TKI, in EGFR-mutant NSCLC models. In vitro studies demonstrated selective growth inhibition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.